Experimental: Lifileucel (LN-144)
All patients will receive LN-144 preceded by an NMA-LD preconditioning regimen consisting of cyclophosphamide and fludarabine. Following LN-144 infusion, up to 6 doses of IV IL-2 will be administered.
Biological: Lifileucel (LN-144)
LN-144 infusion, up to 6 doses of IV IL-2 will be administered.
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
